{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Faldaprevir",
    "query": {
      "intervention": "Faldaprevir"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 17,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Faldaprevir&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T20:28:54.333Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01132313",
      "title": "Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "BI 207127",
          "type": "DRUG"
        },
        {
          "name": "BI 201335",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "BI 207217",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 488,
      "start_date": "2010-05",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2016-02-01",
      "last_synced_at": "2026-09-02T20:28:54.333Z",
      "location_count": 12,
      "location_summary": "La Jolla, California • San Diego, California • San Francisco, California + 9 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Palm Harbor",
          "state": "Florida"
        },
        {
          "city": "Valparaiso",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01132313"
    },
    {
      "nct_id": "NCT00793793",
      "title": "Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "BI201335",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2007-09",
      "completion_date": "2011-01-25",
      "has_results": true,
      "last_update_posted_date": "2018-09-05",
      "last_synced_at": "2026-09-02T20:28:54.333Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Baltimore, Maryland • New York, New York + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00793793"
    },
    {
      "nct_id": "NCT00984620",
      "title": "Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "BI 201335",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Interferon-alpha (IFN)",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin (RBV)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 160,
      "start_date": "2009-09",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2015-09-07",
      "last_synced_at": "2026-09-02T20:28:54.333Z",
      "location_count": 6,
      "location_summary": "Tulepo, Mississippi • New York, New York • Germantown, Tennessee + 3 more",
      "locations": [
        {
          "city": "Tulepo",
          "state": "Mississippi"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Germantown",
          "state": "Tennessee"
        },
        {
          "city": "Jackson",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00984620"
    },
    {
      "nct_id": "NCT01637922",
      "title": "Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "BI 201335",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 34,
      "start_date": "2012-08",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2015-08-03",
      "last_synced_at": "2026-09-02T20:28:54.333Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Overland Park, Kansas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01637922"
    },
    {
      "nct_id": "NCT01728324",
      "title": "Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "BI 207127-placebo: 8-week treatment",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin: 24-week treatment",
          "type": "DRUG"
        },
        {
          "name": "BI 207127: 24-week treatment",
          "type": "DRUG"
        },
        {
          "name": "Faldaprevir: 24-week treatment",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin-placebo: 8-week treatment",
          "type": "DRUG"
        },
        {
          "name": "Faldaprevir-placebo: 8-week treatment",
          "type": "DRUG"
        },
        {
          "name": "Faldaprevir: 16-week treatment",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin: 16-week treatment",
          "type": "DRUG"
        },
        {
          "name": "RBV: 24-week treatment",
          "type": "DRUG"
        },
        {
          "name": "BI 207127: 16-week treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 496,
      "start_date": "2012-11",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2016-02-12",
      "last_synced_at": "2026-09-02T20:28:54.333Z",
      "location_count": 31,
      "location_summary": "North Little Rock, Arkansas • Anaheim, California • Bakersfield, California + 28 more",
      "locations": [
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01728324"
    },
    {
      "nct_id": "NCT01297270",
      "title": "Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "BI201335",
          "type": "DRUG"
        },
        {
          "name": "PegIFN/RBV",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 658,
      "start_date": "2011-04",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2015-09-18",
      "last_synced_at": "2026-09-02T20:28:54.333Z",
      "location_count": 78,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 58 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01297270"
    },
    {
      "nct_id": "NCT01340196",
      "title": "Drug Drug Interaction of BI 201335 and Tenofovir",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "tenofovir/BI 201335",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 16,
      "start_date": "2011-04",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2015-07-31",
      "last_synced_at": "2026-09-02T20:28:54.333Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01340196"
    },
    {
      "nct_id": "NCT01525628",
      "title": "Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "midazolam",
          "type": "DRUG"
        },
        {
          "name": "BI 201335",
          "type": "DRUG"
        },
        {
          "name": "tenofovir",
          "type": "DRUG"
        },
        {
          "name": "caffeine",
          "type": "DRUG"
        },
        {
          "name": "tolbutamide",
          "type": "DRUG"
        },
        {
          "name": "pegylated interferon",
          "type": "DRUG"
        },
        {
          "name": "BI 207127",
          "type": "DRUG"
        },
        {
          "name": "ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 72,
      "start_date": "2012-04",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2016-06-10",
      "last_synced_at": "2026-09-02T20:28:54.333Z",
      "location_count": 5,
      "location_summary": "La Mesa, California • Rockville, Maryland • Marlton, New Jersey + 2 more",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Marlton",
          "state": "New Jersey"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01525628"
    },
    {
      "nct_id": "NCT02593162",
      "title": "A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C Viral Infection",
        "Chronic Hepatitis C",
        "Hepatitis C (HCV)",
        "Hepatitis C Genotype 4"
      ],
      "interventions": [
        {
          "name": "Faldaprevir",
          "type": "DRUG"
        },
        {
          "name": "TD-6450",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trek Therapeutics, PBC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 16,
      "start_date": "2015-10",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2017-01-30",
      "last_synced_at": "2026-09-02T20:28:54.333Z",
      "location_count": 1,
      "location_summary": "Coronado, California",
      "locations": [
        {
          "city": "Coronado",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02593162"
    },
    {
      "nct_id": "NCT01399619",
      "title": "Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "PegIFN/RBV",
          "type": "DRUG"
        },
        {
          "name": "BI201335",
          "type": "DRUG"
        },
        {
          "name": "BI201335 24W",
          "type": "DRUG"
        },
        {
          "name": "Bi 201335",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 310,
      "start_date": "2011-09",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2016-08-29",
      "last_synced_at": "2026-09-02T20:28:54.333Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Palm Springs, California • San Francisco, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01399619"
    }
  ]
}